Effects of Sage on Memory and Mental Performance in Alzheimer's Disease Patients

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Barry S. Oken, Oregon Health and Science University
ClinicalTrials.gov Identifier:
NCT00110552
First received: May 10, 2005
Last updated: January 7, 2013
Last verified: January 2013

May 10, 2005
January 7, 2013
July 2005
December 2012   (final data collection date for primary outcome measure)
Cognitive function [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
Cognitive function
Complete list of historical versions of study NCT00110552 on ClinicalTrials.gov Archive Site
  • Stress [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • cognitive electrophysiology [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Stress
  • cognitive electrophysiology
Not Provided
Not Provided
 
Effects of Sage on Memory and Mental Performance in Alzheimer's Disease Patients
Effects of a Cognitive Enhancer on Memory and Cognitive Performance

The purpose of this study is to determine the effectiveness of the herb sage in improving the mental function of individuals with Alzheimer's disease.

Study hypothesis: The administration of sage will improve cognitive function in patients with mild Alzheimer's disease.

The herb sage has been shown to enhance memory and mental function in healthy, young adults. However, studies assessing the herb's effectiveness in older adults with symptoms of Alzheimer's disease are limited. This study will determine the effect of sage extract on the cognitive function of patients with mild Alzheimer's disease.

This study will last 6 weeks and will comprise 4 study visits, approximately 10 days apart. Participants will be randomly assigned to receive either sage pills or no treatment during each 10-day period. The treatment assignments will be switched in 10-day intervals, so that during the course of the study, each participant will undergo two periods of sage treatment and two periods without treatment. At each study visit, participants will undergo cognitive testing, including tests to determine attention, memory, and visual cognition. Participants will also undergo an electroencephalogram (EEG) and an electrocardiogram (ECG) at each visit.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Basic Science
Alzheimer Disease
Drug: Salvia officinalis (sage)
oral dosage
Other Name: sage
  • Experimental: 1
    Sage capsules taken by mouth
    Intervention: Drug: Salvia officinalis (sage)
  • No Intervention: 2
    No intervention, no-pill as control

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
40
January 2013
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of mild Alzheimer's disease
  • Partner, friend, child, spouse, or relative willing to accompany participants to all study visits, provide informed consent, monitor participants' pill-taking, and communicate changes in participants' health during the study

Exclusion Criteria:

  • Significant medical illness other than Alzheimer's disease
Both
50 Years to 90 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00110552
U19 AT002656-03, U19AT002656-03
Yes
Barry S. Oken, Oregon Health and Science University
Oregon Health and Science University
National Center for Complementary and Alternative Medicine (NCCAM)
Principal Investigator: Barry Oken, MD Oregon Health and Science University
Oregon Health and Science University
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP